- For Print
- May 18, 2017
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a series of abstracts highlighting updates regarding its in-house discovered lenvatinib mesylate (selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, product name: Lenvima® / Kisplyx®, “lenvatinib”), eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: Halaven®, “eribulin”), as well as H3B-8800, a splicing modulator discovered by Eisai's U.S. research subsidiary H3 Biomedicine Inc., will be presented during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from June 2 to 6, 2017.
Detailed data regarding the results of a Phase Ⅲ clinical trial (Study 304) of lenvatinib compared with sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma, which has already achieved its primary endpoint, will be presented orally at the ASCO Annual Meeting. This presentation is scheduled to take place on Sunday, June 4, 8:12 AM local time, in Hall D2.
Major poster presentations will include a highlight of the results of a Phase Ⅰb/Ⅱ clinical trial (Study 111) of lenvatinib in combination with the anti-PD-1 antibody pembrolizumab for the treatment of patients with endometrial carcinoma, and an update regarding a Phase Ⅰ clinical study of H3B-8800 in patients with advanced myeloid malignancies.
Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.
Oral Presentations:
*You can scroll to the left or right here
| Product | Abstract title and scheduled presentation date and time (local time) |
|---|---|
Lenvatinib Abstract No: 4001 |
Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC) |
Major Poster Presentations:
| Product | Abstract title and scheduled presentation date and time (local time) |
|---|---|
Lenvatinib Abstract No: 5598 |
A Phase Ⅰb/Ⅱ Trial of Lenvatinib (LEN) Plus Pembrolizumab (Pembro) in Patients (Pts) With Endometrial Carcinoma Poster Presentation | June 3 (Sat), 1:15-4:45 PM |
Lenvatinib Abstract No: TPS4595 |
A Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab vs Sunitinib Alone in First-Line Treatment of Patients with Advanced Renal Cell Carcinoma |
Lenvatinib Abstract No: 10544 |
Single-agent Dose-finding Cohort of a Phase 1/2 Study of Lenvatinib (LEN) in Children and Adolescents with Refractory or Relapsed Solid Tumors |
Eribulin Abstract No: 6603 |
Validity and Reliability of Four Value Frameworks for Cancer Drugs Poster Presentation | June 5 (Mon), 1:15-4:45 PM |
H3B-8800 Abstract No: TPS7075 |
H3B-8800-G0001-101: A first in human phase I study of a splicing modulator in patients with advanced myeloid malignancies |